These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

276 related articles for article (PubMed ID: 12495846)

  • 21. Biochemistry and structure of phosphoinositide phosphatases.
    Kim YJ; Jahan N; Bahk YY
    BMB Rep; 2013 Jan; 46(1):1-8. PubMed ID: 23351377
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The structure of phosphoinositide phosphatases: Insights into substrate specificity and catalysis.
    Hsu F; Mao Y
    Biochim Biophys Acta; 2015 Jun; 1851(6):698-710. PubMed ID: 25264170
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The tumor suppressor, PTEN/MMAC1, dephosphorylates the lipid second messenger, phosphatidylinositol 3,4,5-trisphosphate.
    Maehama T; Dixon JE
    J Biol Chem; 1998 May; 273(22):13375-8. PubMed ID: 9593664
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Characterization of MTMR3. an inositol lipid 3-phosphatase with novel substrate specificity.
    Walker DM; Urbé S; Dove SK; Tenza D; Raposo G; Clague MJ
    Curr Biol; 2001 Oct; 11(20):1600-5. PubMed ID: 11676921
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A PTEN-related 5-phosphatidylinositol phosphatase localized in the Golgi.
    Merlot S; Meili R; Pagliarini DJ; Maehama T; Dixon JE; Firtel RA
    J Biol Chem; 2003 Oct; 278(41):39866-73. PubMed ID: 12878591
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Assaying phosphoinositide phosphatases.
    Taylor GS; Dixon JE
    Methods Mol Biol; 2004; 284():217-27. PubMed ID: 15173619
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Negative feedback regulation of the tumor suppressor PTEN by phosphoinositide-induced serine phosphorylation.
    Birle D; Bottini N; Williams S; Huynh H; deBelle I; Adamson E; Mustelin T
    J Immunol; 2002 Jul; 169(1):286-91. PubMed ID: 12077256
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Acute regulation of the tumour suppressor phosphatase, PTEN, by anionic lipids and reactive oxygen species.
    Downes CP; Walker S; McConnachie G; Lindsay Y; Batty IH; Leslie NR
    Biochem Soc Trans; 2004 Apr; 32(Pt 2):338-42. PubMed ID: 15046604
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Characterization of an adapter subunit to a phosphatidylinositol (3)P 3-phosphatase: identification of a myotubularin-related protein lacking catalytic activity.
    Nandurkar HH; Caldwell KK; Whisstock JC; Layton MJ; Gaudet EA; Norris FA; Majerus PW; Mitchell CA
    Proc Natl Acad Sci U S A; 2001 Aug; 98(17):9499-504. PubMed ID: 11504939
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Analysis of the cellular functions of PTEN using catalytic domain and C-terminal mutations: differential effects of C-terminal deletion on signalling pathways downstream of phosphoinositide 3-kinase.
    Leslie NR; Gray A; Pass I; Orchiston EA; Downes CP
    Biochem J; 2000 Mar; 346 Pt 3(Pt 3):827-33. PubMed ID: 10698713
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Myotubularin phosphoinositide phosphatases, protein phosphatases, and kinases: their roles in junction dynamics and spermatogenesis.
    Zhang J; Mruk DD; Cheng CY
    J Cell Physiol; 2005 Aug; 204(2):470-83. PubMed ID: 15690393
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Regulation of phosphoinositide metabolism, Akt phosphorylation, and glucose transport by PTEN (phosphatase and tensin homolog deleted on chromosome 10) in 3T3-L1 adipocytes.
    Ono H; Katagiri H; Funaki M; Anai M; Inukai K; Fukushima Y; Sakoda H; Ogihara T; Onishi Y; Fujishiro M; Kikuchi M; Oka Y; Asano T
    Mol Endocrinol; 2001 Aug; 15(8):1411-22. PubMed ID: 11463863
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Pten signaling in gliomas.
    Knobbe CB; Merlo A; Reifenberger G
    Neuro Oncol; 2002 Jul; 4(3):196-211. PubMed ID: 12084351
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Crystal structure of the PTEN tumor suppressor: implications for its phosphoinositide phosphatase activity and membrane association.
    Lee JO; Yang H; Georgescu MM; Di Cristofano A; Maehama T; Shi Y; Dixon JE; Pandolfi P; Pavletich NP
    Cell; 1999 Oct; 99(3):323-34. PubMed ID: 10555148
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The termination of PI3K signalling by SHIP1 and SHIP2 inositol 5-phosphatases.
    Backers K; Blero D; Paternotte N; Zhang J; Erneux C
    Adv Enzyme Regul; 2003; 43():15-28. PubMed ID: 12791379
    [No Abstract]   [Full Text] [Related]  

  • 36. The role of phosphoinositide-3 kinase and PTEN in cardiovascular physiology and disease.
    Oudit GY; Sun H; Kerfant BG; Crackower MA; Penninger JM; Backx PH
    J Mol Cell Cardiol; 2004 Aug; 37(2):449-71. PubMed ID: 15276015
    [TBL] [Abstract][Full Text] [Related]  

  • 37. PTEN: The down side of PI 3-kinase signalling.
    Leslie NR; Downes CP
    Cell Signal; 2002 Apr; 14(4):285-95. PubMed ID: 11858936
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The tumour-suppressor function of PTEN requires an N-terminal lipid-binding motif.
    Walker SM; Leslie NR; Perera NM; Batty IH; Downes CP
    Biochem J; 2004 Apr; 379(Pt 2):301-7. PubMed ID: 14711368
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The myotubularin family: from genetic disease to phosphoinositide metabolism.
    Laporte J; Blondeau F; Buj-Bello A; Mandel JL
    Trends Genet; 2001 Apr; 17(4):221-8. PubMed ID: 11275328
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Targeting mutants of PTEN reveal distinct subsets of tumour suppressor functions.
    Leslie NR; Bennett D; Gray A; Pass I; Hoang-Xuan K; Downes CP
    Biochem J; 2001 Jul; 357(Pt 2):427-35. PubMed ID: 11439092
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.